Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Research
Open Access

Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study

Andrew Mendlowitz, Karen E. Bremner, Jennifer D. Walker, William W.L. Wong, Jordan J. Feld, Beate Sander, Lyndia Jones, Wanrudee Isaranuwatchai and Murray Krahn
September 28, 2021 9 (3) E897-E906; DOI: https://doi.org/10.9778/cmajo.20200247
Andrew Mendlowitz
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
PhD MBiotech
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen E. Bremner
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer D. Walker
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William W.L. Wong
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordan J. Feld
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beate Sander
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyndia Jones
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanrudee Isaranuwatchai
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray Krahn
Institute of Health Policy, Management and Evaluation (Mendlowitz, Sander, Isaranuwatchai, Krahn), University of Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative (Mendlowitz, Bremner, Sander, Krahn), University Health Network; ICES Central (Mendlowitz, Walker, Sander, Krahn), Toronto, Ont.; School of Rural and Northern Health (Walker), Laurentian University, Sudbury, Ont.; School of Pharmacy (Wong), University of Waterloo, Waterloo, Ont.; Toronto Centre for Liver Disease (Feld), Toronto General Hospital; Public Health Ontario (Sander), Toronto, Ont.; Ontario First Nations HIV/AIDS Education Circle (Jones), London, Ont.; St. Michael’s Hospital (Isaranuwatchai), Unity Health Toronto, Toronto, Ont.
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    Flow diagram showing case selection. Note: HCV = hepatitis C virus, OHIP = Ontario Health Insurance Plan.

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Net costs of care per 30 days by cost category for the prediagnosis (A), initial (B), late (C) and terminal (D) phases of care, stratified by residence within or outside of a First Nations community at matching date. Each cost is rounded to the nearest dollar and expressed in 2018 Canadian dollars. “Other” includes Ontario Health Insurance Plan nonphysician services, Assistive Devices Program, rehabilitation services, home care, complex continuing care and long-term care. Error bars represent 95% confidence intervals. Mean cost and net cost results stratified by community status can be found in Appendix 5, Supplemental Tables S8 and S9.

  • Figure 3:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3:

    Net costs of care per 30 days by cost category for the prediagnosis (A), initial (B), late (C) and terminal (D) phases of care, stratified by sex. Each cost is rounded to the nearest dollar and expressed in 2018 Canadian dollars. “Other” includes Ontario Health Insurance Plan nonphysician services, Assistive Devices Program, rehabilitation services, home care, complex continuing care and long-term care. Error bars represent 95% confidence intervals. Mean cost and net cost results stratified by sex can be found in Appendix 5, Supplemental Tables S10 and S11.

Tables

  • Figures
    • View popup
    Table 1:

    Exclusion criteria

    Exclusion criterionDefinition
    Spontaneous clearance
    • Negative HCV RNA test result 12 mo after positive HCV antibody test result and no record of positive HCV RNA test result within 12 mo after first positive test result

    Acute resolved
    • Negative HCV RNA test result within 12 mo after positive HCV RNA test result and no record of HCV-related treatment between testing dates (Appendix 2, Supplemental Table S3, available at www.cmajopen.ca/content/9/3/E897/suppl/DC1)

    • The person never reverted to HCV RNA positive

    HIV infection
    • Record in Ontario HIV database

    • HIV diagnostic code in administrative data (Appendix 2, Supplemental Table S1)

    HBV infection
    • Positive HBV test result in Public Health Ontario testing records

    • HBV diagnostic code in administrative data (Appendix 2, Supplemental Table S1)

    • Note: HBV = hepatitis B virus, HCV = hepatitis C virus.

    • View popup
    Table 2:

    Resource categories included in the cost estimates

    Resource categoryIncluded services*
    Outpatient visitsHospital outpatient clinic services, NACRS visits to dialysis clinics, NACRS visits to cancer clinics
    Physician servicesOHIP physician billings (including fee-for-service and most of the shadow billings†)
    Emergency department visitsNACRS emergency department visits
    Same-day surgerySame-day surgery procedures
    Inpatient careInpatient hospital admissions and OMHRS admissions to designated mental health beds
    Outpatient prescriptionOntario Drug Benefit prescription claims
    Laboratory tests/servicesOHIP laboratory tests
    Other servicesOHIP nonphysician services, Assistive Devices Program, rehabilitation services, home care, complex continuing care and long-term care
    • Note: NACRS = National Ambulatory Care Reporting System, OHIP = Ontario Health Insurance Plan, OMHRS = Ontario Mental Health Reporting System.

    • ↵* Explanations of each administrative database can be found in Appendix 1. Additional details can be found in Appendix 2.

    • ↵† Refers to submitting a claim for services provided for which physicians are paid a small percentage of the usual fee.

    • View popup
    Table 3:

    Characteristics of Status First Nations people in Ontario with HCV infection and matched control participants by phase of care

    CharacteristicCohort; no. (%) of people*
    Prediagnosis phaseInitial phaseLate phaseTerminal phase
    Case
    n = 2096
    Control
    n = 3916
    Case
    n = 2077
    Control
    n = 3875
    Case
    n = 130
    Control
    n = 249
    Case
    n = 297
    Control
    n = 545
    Length of phase, mean ± SD, d179 ± 0179 ± 02714.5 ± 1248.52098.2 ± 966.01280.9 ± 1086.11092.2 ± 826.5168.5 ± 40.2168.3 ± 40.7
    Demographic characteristics
    Age, yr
     Mean ± SD36.7 ± 11.436.9 ± 11.536.7 ± 11.136.8 ± 11.250.1 ± 9.450.1 ± 9.348.8 ± 12.349.5 ± 12.2
     Median (IQR)36 (27–45)36 (27–46)36 (28–45)36 (28–45)50 (46–57)51 (45–57)50 (40–57)51 (41–58)
    Age group, yr
     ≤ 29665 (31.7)1227 (31.3)645 (31.1)1221 (31.5)6 (4.6)10 (4.0)25 (8.4)35 (6.4)
     30–39579 (27.6)1080 (27.6)594 (28.6)1087 (28.1)9 (6.9)19 (7.6)49 (16.5)78 (14.3)
     40–49545 (26.0)1018 (26.0)550 (26.5)1005 (25.9)45 (34.6)82 (32.9)68 (22.9)134 (24.6)
     ≥ 50307 (14.6)591 (15.1)288 (13.9)562 (14.5)70 (53.8)138 (55.4)155 (52.2)298 (54.7)
    Rural mail delivery area
     No2088 (99.6)3897 (99.5)2070 (99.7)3863 (99.7)130 (100.0)249 (100.0)–**539 (98.9)
     Yes8 (0.4)19 (0.5)7 (0.3)12 (0.3)0 (0.0)0 (0.0)–**6 (1.1)
    Sex
     Female944 (45.0)1728 (44.1)945 (45.5)1762 (45.5)42 (32.3)80 (32.1)116 (39.1)205 (37.6)
     Male1152 (55.0)2188 (55.9)1132 (54.5)2113 (54.5)88 (67.7)169 (67.9)181 (60.9)340 (62.4)
    First Nations community status
     Outside of community†1714 (81.8)3142 (80.2)1695 (81.6)3075 (79.4)112 (86.2)216 (86.7)259 (87.2)477 (87.5)
     Within community382 (18.2)774 (19.8)382 (18.4)800 (20.6)18 (13.8)33 (13.3)38 (12.8)68 (12.5)
    Mental health conditions‡
    Alcohol use disorder241 (11.5)377 (9.6)318 (15.3)511 (13.2)28 (21.5)47 (18.9)62 (20.9)117 (21.5)
    Substance-related/addictive disorders§657 (31.3)1136 (29.0)997 (48.0)1787 (46.1)43 (33.1)82 (32.9)113 (38.0)197 (36.1)
    Depression61 (2.9)101 (2.6)96 (4.6)175 (4.5)–**9 (3.6)11 (3.7)19 (3.5)
    Anxiety165 (7.9)284 (7.3)187 (9.0)320 (8.3)–**7 (2.8)22 (7.4)44 (8.1)
    Bipolar10 (0.5)16 (0.4)13 (0.6)23 (0.6)–**–**–**–**
    Schizophrenia spectrum disorder35 (1.7)46 (1.2)45 (2.2)89 (2.3)–**–**7 (2.4)7 (1.3)
    Trauma-/stressor-related disorders38 (1.8)60 (1.5)49 (2.4)94 (2.4)–**–**6 (2.0)8 (1.5)
    Comorbidity‡
    ADGs total score, mean ± SD4.3 ± 3.63.9 ± 3.45.3 ± 3.75.0 ± 3.66.7 ± 4.46.5 ± 4.17.5 ± 4.87.6 ± 4.7
    ADGs total score, median (IQR)4 (1–7)3 (1–6)5 (2–8)4 (2–7)7 (3–10)6 (3–9)7 (4–11)7 (4–11)
    No. of ADGs categories¶
     ≤ 3668 (31.9)1375 (35.1)628 (30.2)1284 (33.1)–**54 (21.7)62 (20.9)95 (17.4)
     4–7702 (33.5)1280 (32.7)762 (36.7)1440 (37.2)41 (31.5)97 (39.0)85 (28.6)164 (30.1)
     8–10251 (12.0)392 (10.0)350 (16.9)578 (14.9)23 (17.7)40 (16.1)52 (17.5)97 (17.8)
     ≥ 11132 (6.3)193 (4.9)203 (9.8)310 (8.0)29 (22.3)47 (18.9)87 (29.3)163 (29.9)
     Nonuser/missing343 (16.4)676 (17.3)134 (6.5)263 (6.8)–**11 (4.4)11 (3.7)26 (4.8)
    • Note: ADGs = Aggregated Diagnosis Groups, HCV = hepatitis C virus, IQR = interquartile range, SD = standard deviation.

    • ↵* Except where noted otherwise.

    • ↵† Also included people who had an out-of-province residence code for the year of matching date.

    • ↵‡ During the year before matching date.

    • ↵§ Also contains records pertaining to alcohol use disorder.

    • ↵¶ The frequencies associated with each specific ADGs category can be found in Appendix 5, Supplemental Table S7.

    • ↵** Suppressed to remove risk of reidentification as per ICES privacy rules.

    • View popup
    Table 4:

    Mean total health care costs per 30 days for case and control participants, by cost category and phase of care

    Resource categoryCohort; mean cost per 30 d, $* (% of total)
    Prediagnosis phaseInitial phaseLate phaseTerminal phase
    CaseControlCaseControlCaseControlCaseControl
    Outpatient visits62 (9.7)31 (10.8)89 (10.2)70 (14.1)227 (8.1)240 (23.7)667 (7.5)738 (9.2)
    Physician services130 (20.3)76 (26.5)168 (19.2)110 (22.1)405 (14.5)151 (14.8)1056 (11.9)875 (10.9)
    Emergency department visits77 (12.0)27 (9.3)55 (6.3)40 (8.0)173 (6.2)57 (5.6)249 (2.8)271 (3.4)
    Same-day surgery8 (1.3)9 (3.1)9 (1.0)10 (2.0)33 (1.2)16 (1.6)17 (0.2)31 (0.4)
    Inpatient care252 (39.6)103 (35.5)325 (37.2)172 (34.7)1307 (46.9)332 (32.7)5929 (66.6)5261 (65.3)
    Outpatient prescription33 (5.2)18 (6.3)150 (17.1)47 (9.5)405 (14.5)105 (10.4)215 (2.4)201 (2.5)
    Laboratory tests/services28 (4.4)11 (3.7)17 (1.9)9 (1.9)21 (0.8)10 (1.0)17 (0.2)12 (0.1)
    Other services†48 (7.5)14 (4.9)62 (7.1)39 (7.8)214 (7.7)104 (10.3)747 (8.4)662 (8.2)
    Total637 (100.0)289 (100.0)875 (100.0)497 (100.0)2786 (100.0)1016 (100.0)8896 (100.0)8050 (100.0)
    • ↵* Costs are rounded to the nearest dollar and expressed in 2018 Canadian dollars.

    • ↵† Costs related to the Assistive Devices Program, nonphysician health care professional services, rehabilitation, home care, complex continuing care and long-term care services.

    • View popup
    Table 5:

    Mean net costs of care per 30 days, by cost category and phase of care

    Resource categoryPhase of care; mean net cost (95% CI) per 30 days, $*
    Prediagnosis phaseInitial phaseLateTerminal
    Outpatient visits31 (12 to 54)19 (−9 to 47)−14 (−190 to 166)−66 (−312 to 193)
    Physician services53 (41 to 65)58 (47 to 69)255 (181 to 338)182 (−34 to 448)
    Emergency department visits50 (43 to 56)15 (10 to 20)116 (66 to 170)−22 (−77 to 30)
    Same-day surgery−1 (−4 to 3)−1 (−2 to 0)17 (3 to 34)−14 (−31 to 1)
    Inpatient care150 (106 to 202)153 (97 to 219)975 (621 to 1378)696 (−975 to 2487)
    Outpatient prescription15 (9 to 20)102 (89 to 115)300 (171 to 443)14 (−73 to 120)
    Laboratory tests/services17 (14 to 20)8 (6 to 9)11 (4 to 21)5 (0 to 10)
    Other services34 (7 to 65)23 (−4 to 54)109 (10 to 205)85 (−198 to 389)
    Total348 (277 to 427)377 (288 to 470)1768 (1153 to 2427)893 (−1114 to 3149)
    • Note: CI = confidence interval.

    • ↵* Costs are rounded to the nearest dollar and expressed in 2018 Canadian dollars.

PreviousNext
Back to top

In this issue

CMAJ Open: 9 (3)
Vol. 9, Issue 3
1 Jul 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study
(Your Name) has sent you a message from CMAJ Open
(Your Name) thought you would like to see the CMAJ Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study
Andrew Mendlowitz, Karen E. Bremner, Jennifer D. Walker, William W.L. Wong, Jordan J. Feld, Beate Sander, Lyndia Jones, Wanrudee Isaranuwatchai, Murray Krahn
Jul 2021, 9 (3) E897-E906; DOI: 10.9778/cmajo.20200247

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study
Andrew Mendlowitz, Karen E. Bremner, Jennifer D. Walker, William W.L. Wong, Jordan J. Feld, Beate Sander, Lyndia Jones, Wanrudee Isaranuwatchai, Murray Krahn
Jul 2021, 9 (3) E897-E906; DOI: 10.9778/cmajo.20200247
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis
  • PubMed
  • Google Scholar

Cited By...

  • Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study
  • Google Scholar

Similar Articles

Collections

  • Clinical
    • Indigenous Health
    • Gastroenterology
      • Liver (including hepatitis and cirrhosis)
    • Public Health
      • Other public health
    • Vulnerable populations
  • Nonclinical
    • Health Economics - see also Medicare

Content

  • Current issue
  • Past issues
  • Collections

About

  • General Information
  • Staff
  • Editorial Board
  • Advisory Panel
  • Contact Us
  • Reprints
  • Copyright and Permissions
CMAJ Group

Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

CMA Civility, Accessibility, Privacy

 

 

Powered by HighWire